Hi ,

You know that human biospecimens represent the best research model, but accessing the right human samples can be challenging. Fortunately, Sanofi’s pipeline matches well with Sanguine’s network of highly characterized, recallable patient donors, so you can choose I/E criteria and timely receive the right samples, including PBMCs and leukopaks. Sanguine’s nationwide donor network includes:

• >13,000 donors with autoimmune indications, our most diverse patient group
• >4000 donors for >800 donors with rare disease, with a growing community of patient advocacy groups research
• >800 donors with rare disease, with a growing community of patient advocacy groups

Sanofi’s commitment to treating inflammatory conditions and Sanguine’s goal of connecting patients to researchers explains why our companies have partnered on over 50 studies. Let’s discuss whether we can continue succeeding for patients.

Warm Regards,

Alison Jones
Research Consultant
Sanguine Bio | Massachusetts


Schedule a Meeting
| www.sanguinebio.com